Prospective evaluation of probabilistic dose-escalated IMRT in prostate cancer
, , , , , , , , and | Dec 22, 2020
About this article
Article Category: Research Article
Published Online: Dec 22, 2020
Page range: 88 - 96
Received: Aug 31, 2020
Accepted: Nov 02, 2020
DOI: https://doi.org/10.2478/raon-2020-0075
© 2021 Daniel Wegener, Bernhard Berger, Zhoulika Outtagarts, Daniel Zips, Frank Paulsen, Martin Bleif, Daniela Thorwarth, Markus Alber, Oliver Dohm, Arndt-Christian Müller, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Figure 3
Figure 4
Patient characteristics of the study cohort
| Parameter | Mean (min.- max.) | Median | n (%) |
|---|---|---|---|
| Age at treatment (years) | 70 (56–83) | 70 | |
| Duration of radiotherapy (weeks) | 7.9 (7.4–8.7) | 7.9 | |
| Gleason-Score (n, %) | |||
| 6 | 4 (14.3 %) | ||
| 7a (3+4) | 15 (53.6 %) | ||
| 7b (4+3) | 9 (32.1 %) | ||
| cTNM (n, %) | |||
| cT1c | 8 (28.6 %) | ||
| cT2a | 8 (28.6 %) | ||
| cT2b | 3 (10.7 %) | ||
| cT2c | 9 (32.1 %) | ||
| Neoadjuvant ADT (n, %) | 22 (78.6 %) | ||
| Duration of ADT (months, range) | 8.9 (3.0–27.0) | 6.0 | |
| Initial PSA peak in ng/ml (range) | 9.1 (1.9–19.8) | 8.3 | |
| PSA-peak by subgroup | |||
| 0 < x ≤ 5 | 3 (10.7 %) | ||
| 5 < x ≤ 10 | 15 (53.6 %) | ||
| 10 < x ≤ 15 | 8 (28.6 %) | ||
| 15 < x ≤ 20 | 2 (7.1 %) |